Skip to main content

Table 6 Incremental cost-utility ratios of ranibizumab referent to laser photocoagulation, intravitreal pegaptanib, and PDT

From: The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

Intervention QALY gain Cost Avr. $/QALY Incr. $/QALYa
Ranibizumab, 2015 1.372 $24,082 $17,552 NA
Laser 0.25717 $1071 $6157 $20,643
Pegaptanib, intravitreal 0.83417 $22,175 $26,589 $3546
PDT 0.74715 $14,057 $18,818 $16,044
  1. All cost-utility analyses in this table use patient utilities, a 3rd party insurer cost perspective and 2nd-eye model. PDT photodynamic therapy with verteporfin, QALY dollars expended per quality-adjusted life year gained, or cost-utility ratio, Avr. $/QALY average cost-utility ratio, Incr. NA not applicable, ranib. ranibizumab therapy. All outcomes and costs are discounted at 3% annually
  2. aIncremental cost-utility ratio of ranibizumab referent to the other interventions